Connect With Us on Twitter
For Op-Ed, follow @nytopinion and to hear from the editorial page editor, Andrew Rosenthal, follow @andyrNYT.
In her Op-Ed article about the Association for Molecular Pathology v. Myriad Genetics case, Eleonore Pauwels refers to "the Supreme Court's unanimous ruling last Thursday, barring patents on human genes" ("Our Genes, Their Secrets," nytimes.com, June 19). Her article doesn't note that the court broadly affirmed the eligibility of patent protection for synthetic DNA and underscored the importance of methods patents for the development of genetic tests.
We agree with Ms. Pauwels that any genetic database used for clinical purposes should be regulated. We believe that medical decisions based on the interpretation of genetic data are crucial to the well-being of patients, and we know of numerous examples in which the clinical use of unregulated public databases has jeopardized patient safety or privacy.
Patients alone should ultimately have the right to decide whether their personal genetic data is deposited into public or government databases. At Myriad, our policies emphasize patient privacy and safety through our regulated laboratory process.
PETER D. MELDRUM
President and Chief Executive
Myriad Genetics
Salt Lake City, June 19, 2013
Anda sedang membaca artikel tentang
Letter: A Ruling on Gene Patents
Dengan url
http://opinimasyarakota.blogspot.com/2013/06/letter-ruling-on-gene-patents.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Letter: A Ruling on Gene Patents
namun jangan lupa untuk meletakkan link
Letter: A Ruling on Gene Patents
sebagai sumbernya
0 komentar:
Posting Komentar